Auceliciclib as Pancreatic Cancer Treatment
Pancreatic cancer has only a five-year survival rate of less than ten per cent, but Aucentra Therapeutics is hoping to reverse this with a new investigational drug call AU3-14 (Auceliciclib). AU3-14 is taken as an oral capsule and demonstrating safety and therapeutic...
Human Trials for Auceliciclib as Glioblastoma Treatment to Begin
Human trials for Auceliciclib, a drug candidate developed by researchers at UniSA designed to treat the most aggressive forms of brain cancer, is set to begin in 2021. Glioblastoma is the most aggressive type of brain cancer, with a 5-year survival rate of...